TXG vs. OLK, CTKB, LAB, BIO.B, BIO, DYN, DNLI, LFST, IRTC, and APGE
Should you be buying 10x Genomics stock or one of its competitors? The main competitors of 10x Genomics include Olink Holding AB (publ) (OLK), Cytek Biosciences (CTKB), Standard BioTools (LAB), Bio-Rad Laboratories (BIO.B), Bio-Rad Laboratories (BIO), Dyne Therapeutics (DYN), Denali Therapeutics (DNLI), LifeStance Health Group (LFST), iRhythm Technologies (IRTC), and Apogee Therapeutics (APGE). These companies are all part of the "medical" sector.
10x Genomics (NASDAQ:TXG) and Olink Holding AB (publ) (NASDAQ:OLK) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their community ranking, dividends, earnings, risk, profitability, media sentiment, analyst recommendations, institutional ownership and valuation.
10x Genomics received 29 more outperform votes than Olink Holding AB (publ) when rated by MarketBeat users. Likewise, 52.56% of users gave 10x Genomics an outperform vote while only 34.29% of users gave Olink Holding AB (publ) an outperform vote.
In the previous week, 10x Genomics had 10 more articles in the media than Olink Holding AB (publ). MarketBeat recorded 14 mentions for 10x Genomics and 4 mentions for Olink Holding AB (publ). Olink Holding AB (publ)'s average media sentiment score of 1.75 beat 10x Genomics' score of 0.46 indicating that Olink Holding AB (publ) is being referred to more favorably in the news media.
10x Genomics has a beta of 1.94, indicating that its stock price is 94% more volatile than the S&P 500. Comparatively, Olink Holding AB (publ) has a beta of 0.5, indicating that its stock price is 50% less volatile than the S&P 500.
10x Genomics presently has a consensus price target of $48.50, suggesting a potential upside of 114.03%. Olink Holding AB (publ) has a consensus price target of $26.00, suggesting a potential upside of 8.74%. Given 10x Genomics' stronger consensus rating and higher probable upside, analysts plainly believe 10x Genomics is more favorable than Olink Holding AB (publ).
Olink Holding AB (publ) has a net margin of -19.72% compared to 10x Genomics' net margin of -42.20%. Olink Holding AB (publ)'s return on equity of -7.07% beat 10x Genomics' return on equity.
Olink Holding AB (publ) has lower revenue, but higher earnings than 10x Genomics. Olink Holding AB (publ) is trading at a lower price-to-earnings ratio than 10x Genomics, indicating that it is currently the more affordable of the two stocks.
84.7% of 10x Genomics shares are owned by institutional investors. Comparatively, 30.2% of Olink Holding AB (publ) shares are owned by institutional investors. 10.0% of 10x Genomics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Summary
10x Genomics beats Olink Holding AB (publ) on 11 of the 18 factors compared between the two stocks.
Get 10x Genomics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TXG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TXG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
10x Genomics Competitors List
Related Companies and Tools
